Medical weight management · UK
A GLP-1 weight-loss clinic, run by a specialist obesity physician.
Wegovy, Saxenda and Mounjaro, prescribed and monitored inside a proper multidisciplinary clinic with a consultant endocrinologist, a dietitian and a psychologist. Not a website with a prescription attached.
Why patients choose us
- 01
A specialist obesity physician, not a prescription-only pharmacy
A named consultant endocrinologist or specialist obesity physician runs your programme, with a dietitian and psychologist in the room. Not a form on a website.
- 02
The right drug for the right person
Wegovy, Saxenda, Mounjaro or a specialist referral for a trial. We match the drug to your BMI, comorbidities and tolerance, and we escalate slowly.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Indicative pricing
What a private GLP-1 programme costs in the UK.
Indicative ranges across our London partner clinics. Weight-loss medication is not usually reimbursed by private insurance. We come back with firm figures across two or three options.
In short
A comprehensive annual programme in our London network: £2,400 to £8,500, all-in with a specialist team.
| Element | Indicative range | Frequency | Turnaround |
|---|---|---|---|
| Initial specialist consultation and screening plan | £280 to £450 | 60 to 90 min | Same visit |
| Monthly monitoring visit and titration | £150 to £280 | 20 to 30 min | Same visit |
| Wegovy (semaglutide) medication, per month | £150 to £280 | Weekly SC | On prescription |
| Saxenda (liraglutide) medication, per month | £180 to £320 | Daily SC | On prescription |
| Mounjaro (tirzepatide) medication, per month | £180 to £280 | Weekly SC | On prescription |
| Comprehensive annual programme (all-in) | £2,400 to £8,500 | 12 months | Ongoing |
Prices vary by clinic, by consultant seniority, by drug and dose, and by how much dietitian and psychology time you use. We confirm a firm quote within one working day.
The problem
The right drug, the right physician, the right team.
A GLP-1 posted from a pharmacy without screening, without titration coaching and without a lifestyle plan is a wasted programme. We stop that happening.
-
Is a GLP-1 the right answer for me?
Not everyone with weight to lose needs one, and not everyone who wants one is eligible. A specialist assesses fit before you commit.
-
Worried about side effects?
Nausea, gastroparesis, pancreatitis and thyroid risk are quoted honestly, with slow titration and a same-day contact plan.
-
Want to keep the weight off?
A dietitian, psychologist and clear maintenance plan, so the weight loss does not evaporate the day the prescription lapses.
The journey
From first enquiry to maintenance - what happens, in order.
One team from first message to long-term maintenance, including the dietitian, the psychologist and the monthly titration reviews.
Phase 1 · Before you start
Screening and matching
Phase 2 · Starting therapy
First dose and titration
Phase 3 · Long term
Monthly then quarterly
- 01
Before
You send us a short medical history
A confidential form. Height, weight, waist, comorbidities (T2DM, OSA, hypertension, NAFLD, cardiovascular disease) and any previous weight-loss attempts or medication.
- 02
Before
We come back with a recommendation
Within one working day: whether a GLP-1 programme fits, which drug is the sensible first choice, indicative price, and what screening bloods we need.
- 03
Before
Screening bloods and comorbidity check
HbA1c, fasting lipids, LFTs, U&Es, TFTs, calcitonin if indicated, and screening for OSA and NAFLD. Rules out MTC, MEN2, active pancreatitis and pregnancy.
- 04
Starting
Your first specialist consultation
60 to 90 minutes with a consultant obesity physician or endocrinologist, a dietitian, and where relevant a psychologist. Consent, dose plan, and injection teaching.
- 05
Starting
First dose and starter titration
A low starting dose (Wegovy 0.25 mg, Mounjaro 2.5 mg, Saxenda 0.6 mg) with four-weekly steps and side-effect coaching between visits.
- 06
Long term
Monthly monitoring and titration
Weight, waist, blood pressure, tolerance and adherence. Dose increases only when side effects allow. Bloods repeated at three and six months.
- 07
Long term
Maintenance and long-term plan
Once you reach a stable dose we move to quarterly reviews. Most people stay on therapy long-term; stopping usually means partial or complete weight regain.
Typical time to first dose: 1 to 2 weeks. Titration to target: 4 to 5 months. Maintenance: long term.
Who is eligible
Where a GLP-1 is the right call - and where it is not.
Licensed indications, high-value comorbidities and the safety flags that mean we redirect to a different plan.
-
BMI 30 or over
The core NICE-recognised indication for pharmacological weight management alongside a reduced-calorie diet and physical activity.
-
BMI 27 or over with a comorbidity
Type 2 diabetes, hypertension, obstructive sleep apnoea, non-alcoholic fatty liver disease or established cardiovascular disease.
-
Type 2 diabetes with obesity
Mounjaro and Wegovy give both glycaemic control and clinically meaningful weight loss, often reducing insulin and other agents.
-
Obstructive sleep apnoea
Tirzepatide is now licensed for moderate to severe OSA in adults with obesity, based on the SURMOUNT-OSA programme.
-
Weight regain after bariatric surgery
Selected patients with post-surgical regain can benefit from a GLP-1 as an adjunct, in a specialist setting.
-
Not for cosmetic weight loss in a normal BMI
We do not prescribe GLP-1 receptor agonists for people with a BMI under 27 who simply want to be slimmer. It is unlicensed and unsafe.
-
Personal or family history of MTC or MEN2
Medullary thyroid carcinoma and MEN2 are contraindications. We ask, we check, and we redirect to non-GLP-1 options.
-
Red flag: pancreatitis, pregnancy, severe gastroparesis
Active or previous pancreatitis, pregnancy or planned pregnancy, and severe gastroparesis mean a different plan.
Drug and programme options
A GLP-1 is a family of drugs - and the lifestyle scaffold sits beside it.
What each option involves and where it fits. Retatrutide is trial-only and is included for context; NHS access is limited to specialist weight-management services.
-
Semaglutide (Wegovy) 0.25 to 2.4 mg weekly
A weekly subcutaneous GLP-1 receptor agonist. STEP-1 showed around 15 percent mean body-weight loss at 68 weeks. NICE TA875 covers specialist NHS use.
-
Liraglutide (Saxenda) 3.0 mg daily
A daily subcutaneous GLP-1, an older option. SCALE showed around 8 percent weight loss at 56 weeks. NICE TA664. Useful when weekly dosing does not suit.
-
Tirzepatide (Mounjaro) 2.5 to 15 mg weekly
A dual GLP-1 and GIP receptor agonist. SURMOUNT-1 showed up to 22 percent mean body-weight loss at 72 weeks. NICE TA1026. The most effective licensed option.
-
Retatrutide (triple agonist), trial-only
A GIP, GLP-1 and glucagon receptor agonist in Phase 3 trials showing about 24 percent weight loss. Not yet licensed. Access is via research programmes only.
-
Dietitian-led calorie and protein plan
A structured calorie deficit with 1.4 to 1.8 g/kg protein to preserve lean mass while weight comes off. Reviewed monthly against your rate of loss.
-
Resistance training and sleep coaching
Two to three resistance sessions a week, sleep hygiene, and alcohol reduction. Protects muscle, mood and long-term adherence.
-
Psychology for eating behaviour
CBT-informed sessions for binge patterns, emotional eating and body image. Improves outcomes and reduces regain when the drug eventually comes down.
-
Second-opinion review of a current programme
A specialist review of your existing regimen and blood results, with a written recommendation on dose, drug switch or exit plan.
Our vetted London network
A small panel of specialist obesity clinics, we picked them.
Cleveland Clinic London Endocrinology, HCA The Wellington Weight Management, King's Private Endocrinology, Chelsea and Westminster Private, Imperial Private Charing Cross, Voy Health and selected GMC-registered obesity physicians. Introductions are made privately once we understand your case.
Selection criteria
How we choose every clinic in our network.
-
GMC-registered consultant obesity physicians and endocrinologists, not prescription-only websites
-
Multidisciplinary teams with a dietitian and access to a psychologist
-
Screening for T2DM, OSA, NAFLD and cardiovascular risk before you start
-
A written exit and maintenance plan, not just a repeat prescription
Safety and side effects
What to expect - honestly.
GLP-1 receptor agonists are well studied and generally well tolerated, but they are potent metabolic drugs. The things worth planning are the first eight weeks of side effects, the surgical pause, and the long-term maintenance plan.
-
Nausea, vomiting, diarrhoea, constipation
The commonest side effects and the main reason people stop. We escalate the dose slowly and coach through the first eight weeks. Most settle.
-
Delayed gastric emptying and surgery
GLP-1 drugs slow the stomach, which matters for anaesthesia. We pause therapy for around three weeks before a planned general anaesthetic to reduce aspiration risk.
-
Pancreatitis and gallstones
Pancreatitis is rare but real, and rapid weight loss raises the risk of gallstones. Severe upper abdominal pain means the drug stops and you are reviewed the same day.
-
Thyroid C-cell safety
Rodent data flagged medullary thyroid tumours; the human picture is unclear. A personal or family history of MTC or MEN2 is a firm contraindication.
-
Retinopathy in T2DM
SUSTAIN-6 flagged a signal for worsening diabetic retinopathy with rapid glucose lowering. We screen retinas before starting in patients with diabetes.
-
Mood, mental health and suicidal ideation
A regulatory signal was investigated and not confirmed; we still screen for depression and eating disorders, and we review mood at every visit.
-
Weight regain if the drug is stopped
The STEP-4 extension showed roughly two-thirds of lost weight returns within a year of stopping. For most people this is long-term therapy, not a short course.
-
Lifestyle is not optional
Calorie deficit, protein intake, resistance training, sleep and alcohol reduction do the structural work. The drug removes the appetite barrier.
-
Red flags after starting
Severe abdominal pain, persistent vomiting, jaundice, a new lump in the neck, or thoughts of self-harm mean the drug stops and you call us the same day.
Reading your treatment plan
Your GLP-1 plan in four parts. Read the last one first.
Whichever drug is chosen, the written plan your specialist sends you keeps to the same shape.
A quiet reminder
Metabolic language can read coldly - we translate it for you.
If you would like us to talk you through the plan before your first review, just ask.
- 01 Header
Diagnosis, BMI and comorbidity summary
Your starting weight, height, BMI, waist circumference and the specific comorbidities that make you eligible for a licensed GLP-1 programme.
- 02 Plan
Drug, dose ladder and monitoring
Which agent, the titration schedule week by week, blood-test intervals and the criteria we use to hold or step down a dose.
- 03 Findings
Response, tolerance and side effects
Percentage body-weight loss so far, HbA1c change if diabetic, blood pressure change, and a plain-English note on side effects and adherence.
- 04 Impression
Maintenance or exit plan
Read this first: are you moving to maintenance, staying on a full dose, switching drug, or planning a slow taper with a lifestyle safety net.
Recognised by major UK insurers
Most UK insurers do not reimburse weight-loss medication itself. Comorbidity screening and specialist consultations may be covered where medically indicated. We confirm cover before booking.
Frequently asked
Everything we get asked about GLP-1 clinics.
Quick answers on mechanism, eligibility, cost, and what happens if you eventually stop.
-
How do GLP-1 receptor agonists actually work?
They are incretin mimetics. They delay gastric emptying so you feel full for longer, they act on hypothalamic appetite centres so you feel less hungry, they suppress glucagon, and they increase insulin release in a glucose-dependent way. The result is a lower calorie intake with better blood-glucose control, which is why they help both weight and type 2 diabetes.
-
Which drug gives the most weight loss?
Currently tirzepatide (Mounjaro) is the most effective licensed option. SURMOUNT-1 showed around 22 percent mean body-weight loss at 72 weeks at the 15 mg dose. Semaglutide (Wegovy) gave around 15 percent at 68 weeks in STEP-1, and liraglutide (Saxenda) around 8 percent at 56 weeks in SCALE. Retatrutide, a triple agonist showing around 24 percent in trials, is not yet licensed.
-
Am I eligible on the NHS?
NHS access is limited to specialist weight-management services, typically for a BMI of 35 or over with type 2 diabetes or another comorbidity, and time-limited (Wegovy up to two years). Waiting lists are long. Private specialist care lets you start within days and stay in one programme long term.
-
What does a private GLP-1 programme cost?
Roughly £280 to £450 for your first specialist consultation and £150 to £280 for each monthly review. Medication ranges from about £150 to £320 a month depending on drug and dose. A comprehensive all-in annual package sits between £2,400 and £8,500. Weight-loss medication is not usually reimbursed by private medical insurance.
-
Do I have to stay on it forever?
For most people, yes, or accept regain. Obesity behaves like a chronic disease: when the drug stops, appetite comes back and about two-thirds of lost weight returns within a year (STEP-4 extension). Some patients maintain on a lower dose with strong lifestyle scaffolding; a minority sustain the loss off-drug.
-
Is it safe to get a GLP-1 from an online pharmacy without a clinic?
We would not recommend it. Without screening you miss thyroid, pancreatic, retinal and mental-health risks; without titration coaching you are more likely to stop from side effects; and without lifestyle support the weight comes back the moment the prescription lapses. Prescription-only supply is not the same as specialist care.
Start with a specialist
Skip the pharmacy website. Start with a consultant.
Send us a short history and we come back within one working day with a named consultant, a drug recommendation, a firm price, and the screening bloods you need.
Related treatments
Looking for something else?
-
Wegovy (semaglutide) programme
Weekly semaglutide, titrated to 2.4 mg for weight loss.
Learn more -
Saxenda (liraglutide)
Daily liraglutide, the older GLP-1 for weight loss.
Learn more -
Mounjaro (tirzepatide) programme
Dual GLP-1 and GIP agonist, the most effective option.
Learn more -
Retatrutide programme
Triple agonist trial-only pathway.
Learn more -
Allurion swallowable balloon
A device-based option for shorter-term weight loss.
Learn more -
Endoscopic sleeve gastroplasty (ESG)
An endoscopic reshaping of the stomach, no incisions.
Learn more -
Obesity
The condition-level guide to obesity in adults.
Learn more -
Type 2 diabetes
The condition-level guide to T2DM.
Learn more